In the BioHarmony Drug Report Database
Rilpivirine
Edurant, Rekambys (rilpivirine) is a small molecule pharmaceutical. Rilpivirine was first approved as Edurant on 2011-05-20. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. Edurant’s patents are valid until 2025-04-21 (FDA).
Trade Name
|
Edurant, Rekambys |
|---|---|
Common Name
|
rilpivirine |
ChEMBL ID
|
CHEMBL175691 |
Indication
|
hiv infections |
Drug Class
|
Antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives |
Image (chem structure or protein)